IL314093A - Agents used for tissue-specific imaging and as therapeutic agents targeting proteins expressed on the surface of muscle cells - Google Patents

Agents used for tissue-specific imaging and as therapeutic agents targeting proteins expressed on the surface of muscle cells

Info

Publication number
IL314093A
IL314093A IL314093A IL31409324A IL314093A IL 314093 A IL314093 A IL 314093A IL 314093 A IL314093 A IL 314093A IL 31409324 A IL31409324 A IL 31409324A IL 314093 A IL314093 A IL 314093A
Authority
IL
Israel
Prior art keywords
tissue
cell surface
therapeutic agents
muscle cell
proteins expressed
Prior art date
Application number
IL314093A
Other languages
English (en)
Hebrew (he)
Original Assignee
Mirecule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirecule Inc filed Critical Mirecule Inc
Publication of IL314093A publication Critical patent/IL314093A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL314093A 2022-01-07 2023-01-06 Agents used for tissue-specific imaging and as therapeutic agents targeting proteins expressed on the surface of muscle cells IL314093A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263297245P 2022-01-07 2022-01-07
PCT/US2023/060253 WO2023133522A2 (en) 2022-01-07 2023-01-06 Tissue-specific imaging and therapeutic agents targeting proteins expressed on muscle cell surface

Publications (1)

Publication Number Publication Date
IL314093A true IL314093A (en) 2024-09-01

Family

ID=87074312

Family Applications (1)

Application Number Title Priority Date Filing Date
IL314093A IL314093A (en) 2022-01-07 2023-01-06 Agents used for tissue-specific imaging and as therapeutic agents targeting proteins expressed on the surface of muscle cells

Country Status (10)

Country Link
US (1) US20250025569A1 (https=)
EP (1) EP4460333A4 (https=)
JP (1) JP2025504375A (https=)
KR (1) KR20240130136A (https=)
CN (1) CN119053346A (https=)
AU (1) AU2023205141A1 (https=)
CA (1) CA3242927A1 (https=)
IL (1) IL314093A (https=)
TW (1) TW202345894A (https=)
WO (1) WO2023133522A2 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413740B1 (en) * 1995-12-15 2002-07-02 Regeneron Pharmaceuticals, Inc. Tyrosine kinase receptors and ligands
US7355018B2 (en) * 2003-09-30 2008-04-08 Regeneron Pharmaceuticals, Inc. Modified IGF1 polypeptides with increased stability and potency
WO2019074489A1 (en) * 2017-10-10 2019-04-18 Flagship Biosciences, Inc. METHODS FOR QUANTITATIVE EVALUATION OF MUSCLE FIBERS IN MUSCLE DYSTROPHY
IL280536B2 (en) * 2018-08-02 2024-12-01 Dyne Therapeutics Inc Complexes targeting transferrin receptor and uses thereof
KR20220125801A (ko) * 2020-01-10 2022-09-14 다인 세라퓨틱스, 인크. 근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도

Also Published As

Publication number Publication date
KR20240130136A (ko) 2024-08-28
WO2023133522A3 (en) 2023-09-28
US20250025569A1 (en) 2025-01-23
EP4460333A4 (en) 2026-01-14
TW202345894A (zh) 2023-12-01
EP4460333A2 (en) 2024-11-13
WO2023133522A2 (en) 2023-07-13
AU2023205141A1 (en) 2024-08-22
CA3242927A1 (en) 2023-07-13
CN119053346A (zh) 2024-11-29
JP2025504375A (ja) 2025-02-12

Similar Documents

Publication Publication Date Title
AU2001297644A1 (en) B/b-like fragment targeting for the purposes of photodynamic therapy and medical imaging
AU2003239531A1 (en) Protein cages for the delivery of medical imaging and therapy
EP1476080A4 (en) ULTRASOUND TREATMENT AND COMPOSITE EXPLANATION OF FAT FABRICS
AU2003277191A8 (en) Targeted tumor therapy by use of recombinant adenovirus vectors that selectively replicate in hypoxic regions of tumors
TW200608993A (en) Tissue-specific imaging and therapeutic agents targeting proteins expressed on lung endothelial cell surface
WO2008103920A3 (en) Targeted protein cages
EP4034132A4 (en) Erk5 degraders as therapeutics in cancer and inflammatory diseases
GB202006974D0 (en) Chimaeric proteins and therapeutic agents
ZA202106237B (en) Preparation and storage of liposomal rna formulations suitable for therapy
EP4408891A4 (en) ANTIBODIES TARGETING BAFF-R AND THEIR USE
IL314093A (en) Agents used for tissue-specific imaging and as therapeutic agents targeting proteins expressed on the surface of muscle cells
IL316101A (en) Skeletal cells refer to solid tumors and their use
WO2007035474A3 (en) Transdermal delivery peptides and method of use thereof
AU2003298794A8 (en) Recombinant immunotoxin and use in treating tumors
AU2003273983A8 (en) Viral vectors and the use of the same for gene therapy
AU2003209150A8 (en) Combination for the treatment of immunoinflammatory disorders and proliferative skin diseases
GB0420734D0 (en) Improvements in or relating to the therapeutic use of radiation and apparatus therefor
WO2006058231A3 (en) Viral vectors
PL4255563T3 (pl) 5’-o-fenyloacetylourydyna i zastosowanie terapeutyczne
AU2003223451A8 (en) Methods for ultrasonic imaging and treating diseased tissues
HRP20041037A2 (en) Binding agents and their use in targeting tumor cells
AU2003298604A8 (en) Materials and methods relating to therapy and diagnosis using targeting of cells that express dcal-hy polypeptides
AU2003295902A8 (en) Methods of therapy and diagnosis using targeting of cells that express p2y10
IL319234A (en) Pyrazolylsulfonamide compounds and their use in therapy
US20220040031A1 (en) Muscle massaging belt assembly